Comparative Pharmacology
Head-to-head clinical analysis: ANHYDRON versus CAPTOPRIL AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANHYDRON versus CAPTOPRIL AND HYDROCHLOROTHIAZIDE.
ANHYDRON vs CAPTOPRIL AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, resulting in vasodilation and decreased aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
1 tablet (captopril 25 mg / hydrochlorothiazide 15 mg) orally once daily, titrated up to a maximum of 1 tablet (captopril 50 mg / hydrochlorothiazide 25 mg) twice daily.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Captopril: ~2 hours (prolonged to 6-8 hours in heart failure or renal impairment). Hydrochlorothiazide: 5.6-14.8 hours (mean ~9.6 hours; prolonged in renal impairment).
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
Captopril: renal (95%), primarily as unchanged drug and disulfide metabolites. Hydrochlorothiazide: renal (≥95%) as unchanged drug via tubular secretion.
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic